Skip to main content
HairCited

Minoxidil için Androgenetik Alopesi

A

191 çalışmaya (19 meta-analyses, 21 RCTs), toplam 41,495 katılımcıyla dayanmaktadır. 159/191 çalışma olumlu etkiler göstermektedir.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Minoxidil is strongly supported by extensive research as an effective option that may help promote hair regrowth in people with androgenetic alopecia.

  • 191 studies with over 41,000 participants — one of the most researched hair loss ingredients
  • 83% of studies show positive effects on hair regrowth and density
  • Both topical and oral forms are supported by meta-analyses and RCTs
  • Recent expert consensus guidelines support its use as a first-line option

Key Study Findings

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo Etki: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss Etki: None None

Popülasyon: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo Etki: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
Case Reports n=1 Open-label
Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: 62-year-old female with diffuse alopecia and plica neuropathica

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs: Placebo Etki: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None

Key Statistics

299

Çalışmalar

68291

Katılımcılar

Positive

A

Derece

Referenced Papers

Journal of the … 2026
Aesthetic plastic surgery 2025 14 atıf
Anais brasileiros de … 2025 7 atıf
Acta dermato-venereologica 2025 4 atıf
European journal of … 2025 3 atıf
Australian prescriber 2025 2 atıf
Journal of clinical … 2025 1 atıf
Nature reviews. Disease … 2025
Archives of dermatological … 2025
Annals of dermatology 2025
International journal of … 2024 39 atıf
Indian journal of … 2024 14 atıf
Journal of cosmetic … 2024 11 atıf
Journal of clinical … 2024 10 atıf
Facial plastic surgery … 2024 8 atıf
Photodermatology, photoimmunology & … 2024 8 atıf
American family physician 2024 8 atıf
Skin health and … 2024 7 atıf
International journal of … 2024 5 atıf
SAGE open medical … 2024 3 atıf
Vestnik oftalmologii 2024 1 atıf
Drugs 2023 221 atıf
JAAD international 2023 80 atıf
Clinical, cosmetic and … 2023 58 atıf
American journal of … 2023 41 atıf
Anais brasileiros de … 2023 29 atıf
Skin appendage disorders 2023 27 atıf
Archives of dermatological … 2023 16 atıf
Journal der Deutschen … 2023 5 atıf
Journal of cosmetic … 2023 3 atıf
BMJ case reports 2023 2 atıf
Clinics in plastic … 2023 1 atıf
International journal of … 2023 1 atıf
The Journal of … 2022 170 atıf
Faculty reviews 2022 44 atıf
Dermatologic therapy 2022 41 atıf
Journal of cosmetic … 2022 35 atıf
Journal of cosmetic … 2022 7 atıf
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 atıf
Journal of the … 2021 42 atıf
Actas dermo-sifiliograficas 2021 3 atıf
Expert opinion on … 2020 147 atıf
International journal of … 2020 58 atıf
Indian dermatology online … 2020 31 atıf
Dermatologic clinics 2020 15 atıf
Facial plastic surgery … 2020 15 atıf
Alternative therapies in … 2020 11 atıf
Drug design, development … 2019 320 atıf
Journal of cosmetic … 2019 100 atıf
American journal of … 2019 84 atıf
Expert opinion on … 2019 34 atıf
Bioscience, biotechnology, and … 2019 9 atıf
Journal of the … 2018 114 atıf
Indian journal of … 2018 79 atıf
Dermatologic therapy 2018 63 atıf
Australian journal of … 2018 8 atıf
American family physician 2017 141 atıf
JAMA dermatology 2017 121 atıf
Current clinical pharmacology 2017 62 atıf
Actas dermo-sifiliograficas 2017 17 atıf
BMJ case reports 2017 6 atıf
Deutsches Arzteblatt international 2016 99 atıf
The Cochrane database … 2016 18 atıf
Current problems in … 2015 8 atıf
Der Internist 2015
Expert opinion on … 2014 57 atıf
Skin therapy letter 2014 29 atıf
Giornale italiano di … 2014 8 atıf
Giornale italiano di … 2014
Indian journal of … 2013 196 atıf
Dermatologic clinics 2013 78 atıf
Journal of cosmetic … 2013 62 atıf
International journal of … 2013 61 atıf
Indian journal of … 2013 16 atıf
Facial plastic surgery … 2013 16 atıf
International journal of … 2013
The Cochrane database … 2012 15 atıf
Expert opinion on … 2010 264 atıf
Current opinion in … 2009 54 atıf
Seminars in cutaneous … 2009 4 atıf
American family physician 2009
Current opinion in … 2008 31 atıf
Nihon rinsho. Japanese … 2008 6 atıf
Endocrinology and metabolism … 2007 33 atıf
Clinical interventions in … 2007
Acta dermatovenerologica Alpina, … 2005
Annual review of … 2004 664 atıf
Revue medicale de … 2004
The journal of … 2003 102 atıf
Praxis 2003 28 atıf
American family physician 2003 2 atıf
American family physician 2003
Clinical and experimental … 2002 61 atıf
Therapeutische Umschau. Revue … 2002 4 atıf
American journal of … 2000 18 atıf
Southern medical journal 2000
International journal of … 1999 16 atıf
Journal of cutaneous … 1999
Journal of the … 1999
International journal of … 1999
American family physician 1999
Dermatologic clinics 1998 121 atıf
Annales de dermatologie … 1997
Journal of the … 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

topical:
2-5% solution, twice daily

Üst sınır: 5% topical solution

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
None -- Mixed 1
varies by agent and study -- Positive --
None -- Positive --
None -- Mixed --

En iyi alım zamanı: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Bildirilen Yan Etkiler

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Bilinen Etkileşimler

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Tolere edilebilir üst alım: 5% topical solution

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Minoxidil help with Androgenetik Alopesi?
Based on 299 studies with 68,291 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Androgenetik Alopesi management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Androgenetik Alopesi?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Androgenetik Alopesi?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 299 peer-reviewed studies with 68,291 total participants. The overall direction of effect is positive.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.